Related Experiment Video
Updated: Jul 15, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
[Treatment of vancomycin-resistant Enterococcus with linezolid in paediatric hospitals]
M Travaglianti1, M Pérez, N Sberna
1Servicio de Farmacia, Hospital de Pediatría Dr. Juan P. Garrahan, Buenos Aires, Argentina. monitravaglianti@yahoo.com.ar
Insights
Linezolid effectively treated vancomycin-resistant Enterococcus infections in critically ill children. While generally well-tolerated, haematological adverse events were noted.
Area of Science:
- Infectious Diseases
- Pediatric Pharmacology
- Antimicrobial Stewardship
Context:
- Vancomycin-resistant Enterococcus (VRE) poses a significant threat in pediatric healthcare settings.
- Limited treatment options exist for VRE infections, especially in critically ill children.
- Linezolid offers a potential therapeutic alternative for VRE infections.
Purpose:
- To evaluate the efficacy and tolerability of linezolid for treating vancomycin-resistant Enterococcus infections in a pediatric hospital.
- To describe the clinical outcomes and adverse events associated with linezolid use in pediatric patients with VRE.
Summary:
- A retrospective study analyzed 15 pediatric patients treated with linezolid for VRE infections between 2002 and 2004.
- Linezolid demonstrated effectiveness in 11 patients (73.3%), with two treatment failures resulting in death.
- Hematological adverse events were the most common side effect, occurring in 55.5% of patients.
Impact:
- Linezolid is an effective and moderately tolerated treatment option for severe VRE infections in children.
- This study highlights the importance of considering linezolid in the management of VRE in pediatric populations.
- Further research may explore optimizing linezolid dosing and monitoring for pediatric VRE treatment.
Objective:
To describe the use of linezolid in vancomycin-resistant Enterococcus infections in a paediatric hospital.
Method:
Retrospective, observational study of hospitalised patients at the "Juan P. Garrahan" paediatric hospital receiving linezolid for the treatment of vancomycin-resistant Enterococcus, during the period between January 2002 and July 2004.
Results:
During 18 months, linezolid was prescribed 17 times for a total of 15 seriously ill patients. The median age was 7 years old (range: 1 month-15 years) and the median length of the treatment was 15 days, with an average hospital stay of 74 days. Infection with vancomycin-resistant Enterococcus was microbiologically documented in 11 (73.3%) patients; they all responded to treatment with linezolid with the exception of two, who died while receiving treatment. The most frequently reported adverse reactions were of a haematological nature (55.5%).
Conclusions:
Linezolid was effective and moderately well tolerated for the treatment of vancomycin-resistant Enterococcus in children with life-threatening infections.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Clinical Significance of Antibiotic Resistance
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Mechanism of Antibiotic Resistance in MRSA
Pharmacokinetics in Pediatric Patients: Drug Distribution
Acute Pyelonephritis II: Diagnostic Studies and Management
